請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16218完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 于明暉(Ming-Whei Yu) | |
| dc.contributor.author | Pei-Yun Cheng | en |
| dc.contributor.author | 鄭佩芸 | zh_TW |
| dc.date.accessioned | 2021-06-07T18:05:31Z | - |
| dc.date.copyright | 2012-09-17 | |
| dc.date.issued | 2012 | |
| dc.date.submitted | 2012-07-25 | |
| dc.identifier.citation | 1. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373(9663):582-92.
2. Kramvis A, Kew M, Francois G. Hepatitis B virus genotypes. Vaccine 2005;23(19):2409-23. 3. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337(24):1733-45. 4. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med 2004;350(11):1118-29. 5. Cane PA, Mutimer D, Ratcliffe D, et al. Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation. Antivir Ther 1999;4(1):7-14. 6. Pan CQ, Zhang JX. Natural History and Clinical Consequences of Hepatitis B Virus Infection. Int J Med Sci 2005;2(1):36-40. 7. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001;120(4):1009-22. 8. Kim HS, Kim HJ, Shin WG, et al. Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2009;136(2):505-12. 9. Liaw YF, Chu CM, Su IJ, et al. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983;84(2):216-9. 10. Lok AS, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol 1990;10(1):29-34. 11. Yuen MF, Yuan HJ, Hui CK, et al. A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut 2003;52(3):416-9. 12. Tsai SL, Chen PJ, Lai MY, et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J Clin Invest 1992;89(1):87-96. 13. Liaw YF, Tai DI, Chu CM, et al. Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients. Hepatology 1987;7(1):20-3. 14. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60. 15. Radziwill G, Tucker W, Schaller H. Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity. J Virol 1990;64(2):613-20. 16. Hunt CM, McGill JM, Allen MI, et al. Clinical relevance of hepatitis B viral mutations. Hepatology 2000;31(5):1037-44. 17. Blum HE. Variants of hepatitis B, C and D viruses: molecular biology and clinical significance. Digestion 1995;56(2):85-95. 18. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009;137(5):1593-608 e1-2. 19. Kidd-Ljunggren K, Miyakawa Y, Kidd AH. Genetic variability in hepatitis B viruses. J Gen Virol 2002;83(Pt 6):1267-80. 20. Palumbo E. Hepatitis B genotypes and response to antiviral therapy: a review. Am J Ther 2007;14(3):306-9. 21. Moskovitz DN, Osiowy C, Giles E, et al. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J Viral Hepat 2005;12(4):398-404. 22. Orito E, Fujiwara K, Tanaka Y, et al. A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Hepatol Res 2006;35(2):127-34. 23. Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 2005;43(3):411-7. 24. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005;97(4):265-72. 25. Wu CF, Yu MW, Lin CL, et al. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis 2008;29(1):106-12. 26. Chu CJ, Lok AS. Clinical significance of hepatitis B virus genotypes. Hepatology 2002;35(5):1274-6. 27. Kramvis A, Kew MC. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat 2005;12(5):456-64. 28. Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998;27(6):1711-6. 29. Yim HJ, Hussain M, Liu Y, et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006;44(3):703-12. 30. Chen CH, Lee CM, Tung WC, et al. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance. J Hepatol 2010;52(4):478-85. 31. Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30(2):567-72. 32. Baptista M, Kramvis A, Kew MC. High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology 1999;29(3):946-53. 33. Chen L, Zhang Q, Yu DM, et al. Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy. J Hepatol 2009;50(5):895-905. 34. Blum HE. Hepatitis B virus: significance of naturally occurring mutants. Intervirology 1993;35(1-4):40-50. 35. Domingo E, Gomez J. Quasispecies and its impact on viral hepatitis. Virus Res 2007;127(2):131-50. 36. Ross HA, Rodrigo AG. Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration. J Virol 2002;76(22):11715-20. 37. Lim SG, Cheng Y, Guindon S, et al. Viral quasi-species evolution during hepatitis Be antigen seroconversion. Gastroenterology 2007;133(3):951-8. 38. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989;2(8663):588-91. 39. Wu S, Imazeki F, Kurbanov F, et al. Evolution of hepatitis B genotype C viral quasi-species during hepatitis B e antigen seroconversion. J Hepatol 2011;54(1):19-25. 40. Ehata T, Omata M, Chuang WL, et al. Mutations in core nucleotide sequence of hepatitis B virus correlate with fulminant and severe hepatitis. J Clin Invest 1993;91(3):1206-13. 41. Ohkawa K, Takehara T, Tatsumi T, et al. Alterations in hepatitis B virus nucleotide sequences in a chronic virus carrier from immunotolerant to immunoactive phase. Biochem Biophys Res Commun 2010;394(3):574-80. 42. Alexopoulou A, Karayiannis P, Hadziyannis SJ, et al. Emergence and selection of HBV variants in an anti-HBe positive patient persistently infected with quasi-species. J Hepatol 1997;26(4):748-53. 43. Okumura A, Takayanagi M, Aiyama T, et al. Serial analysis of hepatitis B virus core nucleotide sequence of patients with acute exacerbation during chronic infection. J Med Virol 1996;49(2):103-109. 44. Liu CJ, Chen PJ, Lai MY, et al. Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. Hepatology 2001;34(3):583-9. 45. Guidotti LG, Rochford R, Chung J, et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;284(5415):825-9. 46. Sung FY, Jung CM, Wu CF, et al. Hepatitis B virus core variants modify natural course of viral infection and hepatocellular carcinoma progression. Gastroenterology 2009;137(5):1687-97. 47. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22(22):4673-80. 48. Tamura K, Peterson D, Peterson N, et al. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011;28(10):2731-9. 49. Huson DH. SplitsTree: analyzing and visualizing evolutionary data. Bioinformatics 1998;14(1):68-73. 50. Lole KS, Bollinger RC, Paranjape RS, et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999;73(1):152-60. 51. Galtier N, Gouy M, Gautier C. SEAVIEW and PHYLO_WIN: two graphic tools for sequence alignment and molecular phylogeny. Comput Appl Biosci 1996;12(6):543-8. 52. Myers R, Clark C, Khan A, et al. Genotyping Hepatitis B virus from whole- and sub-genomic fragments using position-specific scoring matrices in HBV STAR. J Gen Virol 2006;87(Pt 6):1459-64. 53. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 1980;16(2):111-20. 54. Efron B, Halloran E, Holmes S. Bootstrap confidence levels for phylogenetic trees. Proc Natl Acad Sci U S A 1996;93(23):13429-34. 55. T H. BioEdit, version 7.0.9. . Carlsbad, CA: Computer Program and documentation, Ibis Biosciences. 2007. 56. Drummond AJ, Rambaut A, Shapiro B, et al. Bayesian coalescent inference of past population dynamics from molecular sequences. Mol Biol Evol 2005;22(5):1185-92. 57. Felsenstein J, Churchill GA. A Hidden Markov Model approach to variation among sites in rate of evolution. Mol Biol Evol 1996;13(1):93-104. 58. Kao JH, Chen PJ, Lai MY, et al. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118(3):554-9. 59. Sugauchi F, Orito E, Ichida T, et al. Hepatitis B Virus of Genotype B with or without Recombination with Genotype C over the Precore Region plus the Core Gene. J Virol 2002;76(12):5985-5992. 60. Kao JH, Chen DS. Clinical relevance of hepatitis B virus genotypes Ba and Bj in Taiwan. Gastroenterology 2003;125(6):1916-7; author reply 1917-8. 61. Liu CJ, Chen PJ, Lai MY, et al. A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation. Gastroenterology 2003;124(1):80-90. 62. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347(3):168-74. 63. Reignat S, Webster GJ, Brown D, et al. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med 2002;195(9):1089-101. 64. Heo J, Cho M, Kim HH, et al. Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection. J Korean Med Sci 2004;19(4):541-6. 65. Schildgen V, Ziegler S, Tillmann RL, et al. Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - a scholarly case. Virol J 2010;7:167. 66. Asahina Y, Enomoto N, Ogura Y, et al. Sequential changes in full-length genomes of hepatitis B virus accompanying acute exacerbation of chronic hepatitis B. J Hepatol 1996;25(6):787-94. 67. Chauhan R, Kazim SN, Bhattacharjee J, et al. Basal core promoter, precore region mutations of HBV and their association with e antigen, genotype, and severity of liver disease in patients with chronic hepatitis B in India. J Med Virol 2006;78(8):1047-54. 68. Liu F, Chen L, Yu DM, et al. Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy. Gut 2011;60(9):1269-77. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16218 | - |
| dc.description.abstract | 背景與目的: 急性發作(AE)好發於慢性B肝帶原者，尤其是e抗原(HBeAg)呈陽性患者。在感染B型肝炎病毒期間，急性發作被認為和宿主免疫反應和病毒間的平衡被破壞有關，而HBV的變異或許會導致急性發作的產生。為了釐清這個疑惑，本研究主要去探討：(1)B型肝炎病毒polymerase基因區變異與慢性B肝急性發作之相關。(2)慢性B肝患者在歷經急性發作的過程中其血清ALT值和HBV DNA濃度以了解血清HBV DNA 濃度和ALT 值升高的相對應關係。(3)是否有特異的位點變異和急性發作有關。
材料與方法: 我們收集了52位急性發作患者，在收案時(Baseline)、急性發作前(Tb)、急性發作時(Tp)及急性發作之後(Ta)共四個時間點，各別分析了他們的HBV Pol基因序列，並以重疊式病例對照研究法，納入了52位符合配對條件的對照組。總共有160個血清檢體納入研究，接著利用nested PCR將Pol基因區進行放大，並以直接定序的方法進行序列分析。最後，我們分析HBV演化行為及核苷酸/胺基酸變異和急性發作之間的相關。 結果: 在Baseline時急性發作患者其血清ALT和HBV DNA皆顯著高於對照組。而在Baseline時病例組HBV Pol基因多樣顯著低於對照組 (9.68*10-3 vs. 11.7*10-3, p=0.031)，但在急性發作當時(Tp)則看不到這樣的相關(12.1*10-3 vs. 13.8*10-3, p=0.329)。以病例組來探討，急性發作當時(Tp)相較於其它時點(Baseline、Tb、Ta)其平均演化距離高，且達到統計顯著邊緣(12.1*10-3 vs. 10.2*10-3, p=0.071)。最後，經由Pol基因區逐點核苷酸/胺基酸單點變異篩選，我們發現在nt1080 (OR=0.32, p=0.0288)、 nt1126 (OR=0.33, p=0.0453)、 nt1242 (OR=0.34, p=0.0346)、 nt2619 (OR=0.32, p=0.0433)、nt2444 (OR=4.07, p=0.0157)、aa17 (OR=0.28, p=0.048)及aa46 (OR=4.28, p=0.0116)這些位點產生變異會和急性發作的發生有關。 結論：我們的研究顯示並沒有很明顯的證據能說明病毒的歧異度會和急性發作的發生有關。但有些單核苷酸多型性或許可作為急性發作的預測因子。 | zh_TW |
| dc.description.abstract | Background and Aims: Acute exacerbation (AE) occurs frequently in hepatitis B surface antigen (HBsAg) carriers, especially in those positive for HBeAg. During the course of persistent hepatitis B virus (HBV) infection, AE is likely related to the break of balance between virus and host immune response, and HBV genetic variation may trigger AE. The aim of this study was to clarify the association between HBV sequence variations and AE, and to investigate change in Pol gene sequence before, during, and after exacerbation.
Materials and Methods: We prospectively studied 52 patients with exacerbation of hepatitis B Pol gene sequence using plasma sample collected at baseline, before alanine aminotransferase (ALT) peak, ALT peak, and after ALT peak, respectively. Fifty-two subjects who h ad persistently normal serum ALT during follow-up served as controls. A total of 160 HBV DNA samples were amplified by nested polymerase chain reaction (PCR) from sera and were directly sequenced. We then analyze the relationship between HBV evolutionary pattern and specific nucleotide/amino acid variants and acute exacerbation. Results: AE cases had a significantly higher level of serum ALT and HBV DNA than controls at baseline. Baseline genetic distance was statistically lower in cases than in controls at the nucleotide level (9.68*10-3 vs. 11.7*10-3, p=0.031), but no such association was found at ALT peak (12.1*10-3 vs. 13.8*10-3, p=0.329). Among AE cases, the genetic distance was also higher at ALT peak when compare with other time points at marginal statistical significance (12.1*10-3 vs. 10.2 *10-3, p=0.071). After point-by-point screening the nucleotide/amino acid positions in the whole Pol gene region, we have revealed the association between AE and variant types at nucleotide and amino acid positions, nt1080 (OR 0.32, p 0.0288), nt1126 (OR 0.33, p 0.0453), nt1242 (OR 0.34, p 0.0346), nt2619 (OR 0.32, p 0.0433), nt2444 (OR 4.07, p 0.0157), aa17 (OR 0.28, p 0.048), aa46 (OR 4.28, p 0.0116) . Conclusion: Our data suggest no clear evidence for the association between rate of viral divergence and the occurrence of AE. Certain single nucleotide polymorphism may serve as predictive of AE. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-07T18:05:31Z (GMT). No. of bitstreams: 1 ntu-101-R99849020-1.pdf: 1330737 bytes, checksum: 123a16d9058bcb25717f670212749241 (MD5) Previous issue date: 2012 | en |
| dc.description.tableofcontents | 中文摘要 iii
Abstract iv 研究背景 1 材料與方法 7 結果 12 討論 17 參考文獻 22 | |
| dc.language.iso | zh-TW | |
| dc.title | B型肝炎病毒polymerase基因區變異與慢性B肝急性發作之相關:縱式研究 | zh_TW |
| dc.title | Viral Polymerase Genetic Variation and Acute Exacerbation in Chronic Hepatitis B: Longitudinal Study | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 100-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 劉信孚(Hsin-Fu Liu),鄭如茜(Ju-Chien Cheng),林志陵(Chih-Ling Lin) | |
| dc.subject.keyword | 慢性B 型肝炎,B 型肝炎病毒,急性發作,病毒演化,基因多樣性,病毒量, | zh_TW |
| dc.subject.keyword | Chronic HBV infection,Hepatitis B Virus,Acute exacerbation(AE),ALT,evolution,diversity, | en |
| dc.relation.page | 45 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2012-07-26 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-101-1.pdf 目前未授權公開取用 | 1.3 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。